| Original language | English (US) |
|---|---|
| Pages (from-to) | e206 |
| Journal | The Lancet HIV |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2018 |
Bibliographical note
Funding Information:J-MM is an advisory board member of Gilead Sciences, Merck, Janssen, ViiV Healthcare, and Teva, and has received grants from Gilead Sciences and Merck, outside the submitted work. BG reports grants from National Institutes of Health and National Institute of Allergy and Infectious Diseases, during the conduct of the study.